Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) Director Christopher Kiritsy sold 313 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total transaction of $49,141.00. Following the completion of the transaction, the director directly owned 250 shares of the company’s stock, valued at approximately $39,250. This trade represents a 55.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Palvella Therapeutics Price Performance
NASDAQ:PVLA traded up $1.77 on Friday, hitting $157.24. 162,218 shares of the company’s stock were exchanged, compared to its average volume of 265,893. The firm has a 50-day moving average price of $148.17 and a 200-day moving average price of $129.27. Palvella Therapeutics, Inc. has a 52 week low of $52.36 and a 52 week high of $161.38. The company has a market cap of $2.27 billion, a P/E ratio of -32.55 and a beta of -0.25.
Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, research analysts expect that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Palvella Therapeutics
Analyst Ratings Changes
A number of brokerages have recently issued reports on PVLA. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Truist Financial set a $207.00 target price on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Stephens reiterated an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $209.14.
Check Out Our Latest Stock Analysis on Palvella Therapeutics
Palvella Therapeutics Company Profile
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Read More
- Five stocks we like better than Palvella Therapeutics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
